Desmoid tumors in the hereditary context are associated with variants in the APC gene, located on chromosome 5. This form of the condition is inherited in an autosomal dominant pattern, in which a single copy of the altered gene is sufficient for susceptibility and each first-degree relative of an affected individual has a 50% chance of inheriting the variant. The location of pathogenic variants along the APC gene influences the likelihood of desmoid tumor development; variants in different codon regions of the gene have been associated with differing incidence rates of desmoid tumor development among APC variant carriers. A distinct subtype of desmoid tumor arises through somatic mutation, a post-zygotic process in which the genetic change occurs during development and is not present in germline cells; this form does not follow familial inheritance patterns. Importantly, not all individuals who carry a hereditary APC variant will develop desmoid tumors, reflecting incomplete penetrance of this specific manifestation — the majority of carriers do not develop tumors. The type and severity of tumor development among those who are affected also varies considerably from person to person, consistent with variable expressivity. Abdominal surgery has been identified as a circumstance that may increase the risk of desmoid tumor development in individuals at hereditary risk.

The presence of a desmoid tumor, particularly when accompanied by colorectal polyposis or a family history of APC-associated conditions, may prompt evaluation for a hereditary etiology. Molecular genetic testing of the APC gene, encompassing sequencing and deletion/duplication analysis, can identify heterozygous germline pathogenic variants associated with the hereditary form of the condition. A desmoid tumor is recognized as a clinical feature suggestive of underlying APC-associated polyposis conditions, and its identification may inform broader genetic evaluation. For the sporadic subtype attributable to somatic mutation, the genetic change is not present in germline tissue and would not be identified through standard germline hereditary testing. The scope and approach to diagnostic workup is determined by clinical presentation, family history, and individual clinical circumstances.

Nirogacestat (Ogsiveo) is an FDA-approved treatment for desmoid tumor, representing a targeted therapeutic approach developed specifically for this condition. Several additional therapeutic candidates hold orphan designation for desmoid tumor and are under active investigation in clinical trials; these agents are not currently approved for clinical use. Treatment planning for desmoid tumor involves individualized assessment by a multidisciplinary team and takes into account factors including tumor size, location, behavior, and individual patient characteristics. Management approaches may encompass systemic medical therapy, procedural interventions including embolization or ablation, surgical options where clinically indicated, or active surveillance, with goals determined by the specific clinical situation. The management of desmoid tumor in the context of APC-associated conditions may also involve coordination with specialists addressing the broader disease spectrum. Patient assistance programs may be available to help cover treatment costs.

Desmoid tumors are distinguished from malignant neoplasms by the absence of metastatic potential; these tumors do not spread to distant sites. However, the locally invasive behavior of desmoid tumors and their high rate of local recurrence are recognized features that contribute to clinical complexity and morbidity. The clinical course among affected individuals is variable; tumor behavior may range from clinically stable or spontaneously regressing to locally progressive, with involvement of adjacent structures leading to significant complications in some cases. Tumor location is a key determinant of associated morbidity, as tumors affecting critical anatomical structures carry greater potential for functional consequences than those in less critical sites. In individuals with hereditary forms of the condition, the broader clinical context of APC-associated disease also contributes to the overall clinical picture and long-term management considerations.

Desmoid tumor is the focus of numerous ongoing clinical investigations, with active trials spanning multiple phases and examining drug therapies, procedural interventions, and observational approaches. Research encompasses both targeted systemic therapies and interventional techniques such as arterial chemoembolization and cryoablation, reflecting the breadth of approaches under evaluation. The published literature on desmoid tumor includes numerous case reports and case series, as well as review articles and biomarker and trial-related publications, indicating an active and evolving research landscape. Active clinical trials for this condition are listed on ClinicalTrials.gov.